Description General description A potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (Ki = 16 nM; IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells. A 1 mg/ml solution of SB 202190 (Cat. No. 559397) in anhydrous DMSO is also available. A potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (Ki = 16 nM; IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells. Packaging 1 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target p38β Product competes with ATP. Reversible: yes Target IC50: 350 nM against the kinase activity of p38β; 280 nM against p38 phosphorylation of activating transcription factor 2 (ATF-2) Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. Other Notes Davies, S.P., et al. 2000. Biochem. J.351, 95. Ajizian, S.J., et al. 1999. J. Infect. Dis.179, 939. Singh, R.P., et al. 1999. J. Biol. Chem.274, 19593. Wang, S.W., et al. 1999. Inflamm. Res.48, 533. Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49. LoGrasso, P.V., et al. 1997. Biochem. 36, 10422. Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920. Kramer, R.M., et al. 1996. J. Biol. Chem.271, 27723. Li, Z., et al. 1996. Biochem. Biophys. Res.Commun. 228, 334. Lee, J.C., et al. 1994. Nature 372, 739.